Early Diagnosis of Fabry Disease in a Patient with Toe Tip Pain
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Fabry disease is an X-linked lysosomal disease caused by deficiency of a-galactosidase, in which early diagnosis may be missed due to the wide variety of clinical symptoms presenting during disease progression. A 13 year-old boy visited our pain clinic complaining of pricking and burning pain in the toe tips of both feet. Continuous epidural infusion for pain management was performed because of oral analgesics ineffectiveness. The patient underwent a-galactosidase A (GLA) enzyme analysis based on the clinical impression of Fabry disease from pain with a peripheral neuropathic component and history of anhidrosis. He was diagnosed with Fabry disease after confirming mutation of the GLA gene through a screening test of GLA activity. Enzyme replacement therapy was initiated and pain was tolerated with oral analgesics. (Korean J Pain 2010; 23: 207-210)
Abstract
Fabry disease is an X-linked lysosomal disease caused by deficiency of a-galactosidase, in which early diagnosis may be missed due to the wide variety of clinical symptoms presenting during disease progression. A 13 year-old boy visited our pain clinic complaining of pricking and burning pain in the toe tips of both feet. Continuous epidural infusion for pain management was performed because of oral analgesics ineffectiveness. The patient underwent a-galactosidase A (GLA) enzyme analysis based on the clinical impression of Fabry disease from pain with a peripheral neuropathic component and history of anhidrosis. He was diagnosed with Fabry disease after confirming mutation of the GLA gene through a screening test of GLA activity. Enzyme replacement therapy was initiated and pain was tolerated with oral analgesics. (Korean J Pain 2010; 23: 207-210)
참고문헌 (20)
- Brady RO, "Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency", N Engl J Med, 276, pp.1163~1167 (1967)
- Scriver CR, "The metabolic & molecular bases of inherited disease. 8th ed", pp.3733~3774 (2001), McGraw-Hill
- Eng CM, "Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry", J Inherit Metab Dis, 30, pp.184~192 (2007)
- Meikle PJ, "Prevalence of lysosomal storage disorders", JAMA, 281, pp.249~254 (1999)
- Ramaswami U, "Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey", Acta Paediatr, 95, pp.86~92 (2006)
- Ries M, "The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents", Eur J Pediatr, 162, pp.767~772 (2003)
- Manger B, "Rheumatologic aspects of lysosomal storage diseases", Clin Rheumatol, 26, pp.335~341 (2007)
- Mehta A, "Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey", Eur J Clin Invest, 34, pp.236~242 (2004)
- Wozniak MA, "Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke", Stroke, 41, pp.78~81 (2010)
- Kotanko P, "Results of a nationwide screening for Anderson-Fabry disease among dialysis patients", J Am Soc Nephrol, 15, pp.1323~1329 (2004)
- Marchesoni CL, "Misdiagnosis in Fabry disease", J Pediatr, 156, pp.828~831 (2010)
- Paira SO, "Joint manifestations of Fabry's disease", Clin Rheumatol, 11, pp.562~565 (1992)
- Madden S, "Update on acute rheumatic fever: it still exists in remote communities", Can Fam Physician, 55, pp.475~478 (2009)
- Hoffmann B, "Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey", Clin J Pain, 23, pp.535~542 (2007)
- Hoffmann B, "Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)", J Med Genet, 42, pp.247~252 (2005)
- Hoffmann B, "Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy", Clin Gastroenterol Hepatol, 5, pp.1447~1453 (2007)
- Feriozzi S, "Survey Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease", Am J Nephrol, 29, pp.353~361 (2009)
- Hughes DA, "Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa", Heart, 94, pp.153~158 (2008)
- Wraith JE, "Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease", J Pediatr, 152, pp.563~570 (2008)
- Banikazemi M, "Agalsidase-beta therapy for advanced Fabry disease: a randomized trial", Ann Intern Med, 146, pp.77~86 (2007)